NCT03108456进行中（未招募）不适用
Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 2,005
- 试验地点
- 104
- 主要终点
- Target Vessel Failure (TVF)
研究概览
简要总结
This trial will evaluate Orbital Atherectomy compared to conventional balloon angioplasty technique for the treatment of severely calcified lesions prior to implantation of drug-eluting stents (DES).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •General Inclusion Criteria:
- •Subject is 18 years of age or older.
- •Subject presents with:
- •stable ischemic heart disease or
- •acute coronary syndrome (NSTEMI or unstable angina), or
- •stabilized recent STEMI (>48 hours prior to randomization procedure)
- •Subject has signed the Institutional Review Board (IRB) or Ethics Committee (EC) approved ECLIPSE trial Informed Consent Form (ICF) prior to any trial related procedures.
排除标准
- •Subject has a history of any cognitive or mental health status that would interfere with trial participation.
- •Subject is participating in or has plans to participate in any other investigational drug or device trial that has not reached its primary endpoint.
- •Subject is a female who is pregnant.
- •Subject is receiving or scheduled to receive chemotherapy within thirty (30) days prior or any time after the randomization procedure.
- •Subject has a life expectancy of ≤ 12 months.
- •Subject has undergone any prior PCI in the target vessel or its branches 12 months prior to randomization.
- •Subject has undergone a PCI procedure that is unsuccessful or with complications within 30 days prior to randomization, including during the randomization procedure.
- •Any cardiac intervention or cardiac surgery planned within 12 months post randomization procedure aside from a potential planned staged PCI as part of the randomized treatment strategy.
- •Subject has major valve disease and underwent intervention within 30 days prior to randomization.
- •Subject has received a heart transplant.
- •Evidence of heart failure by at least one of the following (heart failure assessment is not required per protocol but must be reviewed prior to enrollment if data is available):
- •Most recent LVEF ≤25%, or
- •Current heart failure defined as dyspnea at rest (NYHA class IV assessed day of procedure), or
- •Killip class ≥2 (post STEMI patients)
- •Planned use in the randomized lesion(s) of a bare metal stent (BMS), bioresorbable scaffold (BRS), non-stent treatment only.
- •Subject has a known sensitivity to contrast media, which cannot be adequately pre-medicated.
- •Subject has a relative or absolute contraindication to dual antiplatelet therapy or (for patients with atrial fibrillation) single antiplatelet therapy (P2Y12 inhibitor preferred) with an anticoagulant for at least 6 months after PCI.
- •Subject has a history of a stroke or transient ischemic attack (TIA) within six (6) months prior to randomization, or any permanent neurologic deficit.
- •Subject has a history of bleeding diathesis or coagulopathy or intention to refuse blood transfusion if one should become necessary.
- •Subject has evidence of an active infection on the day of the randomization procedure requiring oral or intravenous antibiotics.
- •Subject with known allergy to atherectomy lubricant components including soybean oil, egg yolk phospholipids, glycerin and sodium hydroxide.
研究组 & 干预措施
Orbital Atherectomy (OA)
Active Comparator
The Diamondback 360® Coronary Orbital Atherectomy System (OAS) will be used for orbital atherectomy (OA) vessel preparation prior to implantation of a drug-eluting stent.
干预措施: Orbital Atherectomy (Device)
Conventional Balloon Angioplasty
Active Comparator
Coronary balloons cleared or approved for commercial use by the Food and Drug Administration will be used for conventional balloon angioplasty prior to implantation of a drug-eluting stent.
干预措施: Balloon (Device)
结局指标
主要结局
Target Vessel Failure (TVF)
时间窗: 1-Year
Target vessel failure, defined as the composite of cardiac death, target vessel related myocardial infarction (MI), or ischemia-driven target vessel revascularization.
Acute Minimum Stent Area (MSA)
时间窗: Procedure
In-stent minimal cross-sectional area as assessed by optical coherence tomography (OCT) at the conclusion of the procedure in the OCT imaging cohort.
次要结局
- Procedural Success(Procedure)
- Strategy Success(Procedure)
研究者
研究点 (104)
Loading locations...
相似试验
Unknown
不适用
Palpitate-Eluting Balloon Angioplasty in the Treatment of Coronary Bifurcation Lesion Evaluated by OCTPercutaneous Coronary InterventionAngioplastyNCT02276846Second Hospital of Jilin University30
招募中
不适用
Calcium Reduction by Orbital Atherectomy in Western EuropeVascular CalcificationAtherectomies, CoronaryHumansVascular Calcification* / Diagnostic ImagingTomography, Optical CoherenceCoronary AngiographyTreatment OutcomeCoronary Intervention, PercutaneousVascular Calcification* / TherapyNCT06035783Erasmus Medical Center100
招募中
不适用
Trial of Orbital Atherectomy Versus Standard Strategy in Calcified Bifurcation LesionsCoronary DiseaseCoronary Artery DiseaseNCT06736899Fundación EPIC200
尚未招募
4 期
Orbital Atherectomy vs Intravascular Lithotripsy for the Treatment of Calcified Coronary Nodules (ORBIT-SHOCK).Coronary Arterial Disease (CAD)Coronary Calcified NodulesCoronary CalcificationOrbital AtherectomyIntravascular LithotripsyOptical Coherence Tomography (OCT)Percutaneous Coronary Intervention (PCI)Acute Coronary Syndrome (ACS)Chronic Coronary SyndromeNCT06736665Spanish Society of Cardiology50
已完成
不适用
Directional Versus Orbital Atherectomy Plaque Modification and Luminal Area Assessment of the Femoro-popliteal Artery Via Intravascular UltrasoundPeripheral Artery DiseaseNCT03495453NYU Langone Health94